Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Ectopic expression of FGF-3 results in abnormal prostate and Wolffian duct development

Abstract

To evaluate the effects of FGF-3 expression in the prostate and male reproductive tract, we employed a bitransgenic system to target FGF-3 to these organs. We present a first study that ectopic FGF-3 expression resulted in exuberant hyperplasia of all bigenic prostatic lobes typified by epithelial stratification, cribiform structures and papillary tufts. These cells displayed increased nuclear-to-cytoplasmic ratios and bromodeoxyuridine (BrdU) proliferative index but retained relatively uniform nuclear androgen receptor (AR) and the tumor suppressor C-CAM1 staining. Furthermore, the dysmorphogenic prostatic cells also resembled PIN (prostatic intraepithelial neoplasia)-like lesions but did not appear to have invaded the basal lamina. In addition to these phenotypes, profound disorders of the bigenic Wolffian duct derivatives were observed. The bigenic ampullary glands and vas deferens were extremely cystic, hypertrophic and hyperplastic; the enlarged epididymi showed a reduction of spermatozoa and the seminal vesicles exhibited a dramatic reduction of seminal secretions. Because of these severe abnormalities, these infertile males presented with diaphragmatic hernias, hemoperitoneum and many secondary abnormalities at sacrifice. Taken together, we show that ectopic FGF-3 expression severely perturbs normal prostate development and our system should be useful for the analyses of early changes in prostatic hyperplasia.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Antoine M, Reimers K, Dickson C, Kiefer P . 1997 J. Biol. Chem. 272: 29475–29481

  • Basilico C, Moscatelli D . 1992 Adv. Cancer Res. 59: 115–165

  • Burgess WH, Maciag T . 1989 Annu. Rev. Biochem. 58: 575–606

  • Callahan R . 1996 Breast Cancer Res. Treat. 39: 33–44

  • Chung JH, Whiteley M, Felsenfeld G . 1993 Cell 74: 505–514

  • Church GM, Gilbert W . 1984 Proc. Natl. Acad. Sci. USA 81: 1991–1995

  • Cox KH, DeLeon DV, Angerer LM, Angerer RC . 1984 Dev. Biol. 101: 485–502

  • Darbre P, Page M, King RJ . 1986 Mol. Cell. Biol. 6: 2847–2854

  • Dickson C, Peters G . 1987 Nature 326: 833–

  • Dietrich WF, Lander ES, Smith JS, Moser AR, Gould KA, Luongo C, Borenstein N, Dove W . 1993 Cell 75: 631–639

  • Donjacour AA, Thomson AA, Cunha GR . 1998 Differentiation 62: 227–237

  • Feng S, Wang F, Matsubara A, Kan M, McKeehan WL . 1997 Cancer Res. 57: 5369–5378

  • Foster BA, Kaplan PA, Greenberg NM . 1999 Prost. Cancer Prost. Dis. 2: 76–82

  • Gingrich JR, Barrios RJ, Foster BA, Greenberg NM . 1999 Prost. Cancer Prost. Dis. 2: 70–75

  • Gospodarowicz D, Greenburg G, Bialecki H, Zetter BR . 1978 In Vitro 14: 85–118

  • Gunzburg WH, Salmons B . 1992 Biochem. J. 283: 625–632

  • Ham J, Thomson A, Needham M, Webb P, Parker M . 1988 Nucleic Acids Res. 16: 5263–5276

  • Ittman M, Mansukhani A . 1997 J. Urol. 157: 351–356

  • Jakobovits A, Shackleford GM, Varmus HE, Martin GR . 1986 Proc. Natl. Acad. Sci. USA 83: 7806–7810

  • Johnson DE, Williams LT . 1993 Adv. Cancer Res. 60: 1–41

  • Kiefer P, Acland P, Pappin D, Peters G, Dickson C . 1994 EMBO J. 13: 4126–4136

  • Kiefer P, Dickson C . 1995 Mol. Cell. Biol. 15: 4364–4374

  • Ma ZQ, Chua SS, DeMayo FJ, Tsai SY . 1999 Oncogene 18: 4564–4576

  • Mansour SL, Goddard JM, Capecchi MR . 1993 Development 117: 13–28

  • Mathieu M, Chatelain E, Ornitz D, Bresnick J, Mason I, Kiefer P, Dickson C . 1995 J. Biol. Chem. 270: 24197–24203

  • Muller WJ, Lee FS, Dickson C, Peters G, Pattengale P, Leder P . 1990 EMBO J. 9: 907–913

  • Ornitz DM, Moreadith RW, Leder P . 1991 Proc. Natl. Acad. Sci. USA 88: 698–702

  • Peters G, Brookes S, Smith R, Dickson C . 1983 Cell 33: 369–377

  • Prins GS, Birch L . 1995 Endocrinology 136: 1303–1314

  • Pu YS, Luo W, Lu HH, Greenberg NM, Lin SH, Gingrich JR . 1999 J. Urol. 162: 892–896

  • Rifkin DB, Moscatelli D . 1989 J. Cell Biol. 109: 1–6

  • Robinson ML, Ohtaka-Maruyama C, Chan CC, Jamieson S, Dickson C, Overbeek PA, Chepelinsky AB . 1998 Dev. Biol. 198: 13–31

  • Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P . 1987 Cell 49: 465–475

  • Stamp G, Fantl V, Poulsom R, Jamieson S, Smith R, Peters G, Dickson C . 1992 Cell Growth Differ. 3: 929–938

  • Tekmal RR, Keshava N . 1997 Front Biosci. 2: d519–d526

  • Thomson AA, Foster BA, Cunha GR . 1997 Development 124: 2431–2439

  • Thomson AA, Cunha GR . 1999 Development 126: 3693–3701

  • Thomson AA . 2001 Reproduction 121: 187–195

  • Wang Y, O'Malley Jr BW, Tsai SY, O'Malley BW . 1994 Proc. Natl. Acad. Sci. USA 91: 8180–8184

  • Wang Y, DeMayo FJ, Tsai SY, O'Malley BW . 1997a Nat. Biotechnol. 15: 239–243

  • Wang Y, Xu J, Pierson T, O'Malley BW, Tsai SY . 1997b Gene Ther. 4: 432–441

  • Wilkinson DG, Peters G, Dickson C, McMahon AP . 1988 EMBO J. 7: 691–695

  • Wilkinson DG, Bhatt S, McMahon AP . 1989 Development 105: 131–136

  • Xue L, Yang K, Newmark H, Lipkin M . 1997 Carcinogenesis 18: 995–999

  • Yamamoto KR . 1985 Annu. Rev. Genet. 19: 209–252

  • Yamashita T, Yoshioka M, Itoh N . 2000 Biochem. Biophys. Res. Comm. 277: 494–498

  • Yan G, Fukabori Y, McBride G, Nikolaropolous S, McKeehan WL . 1993 Mol. Cell. Biol. 13: 4513–4522

  • Zhao B, Chua SS, Burcin MM, Reynolds SD, Stripp BR, Edwards RA, Finegold MJ, Tsai SY, DeMayo FJ . 2001 Proc. Natl. Acad. Sci. USA 98: 5898–5903

Download references

Acknowledgements

We thank Drs Roberto Barrios, Barbara Foster, Paula Kaplan and Fred A Pereira for their valuable help, advice and critical discussions; Drs Brigid Hogan, Jay Chung and Susanne Mansour for their generous gift of the MMTV-KCR, HS4 insulator and murine FGF-3 plasmids respectively; Dr Phil Leder for the FGF-3 target mice and Dr Gail Prins for the AR antibody. We are also grateful to LouAnn Hadsell and John Stockton for their excellent technical support. This work was supported by DOD and NIH grants to SY Tsai, an ACS RPG-95-020-04 grant to FJ DeMayo and a DOD fellowship to Z-Q Ma.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sophia Y Tsai.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chua, S., Ma, ZQ., Gong, L. et al. Ectopic expression of FGF-3 results in abnormal prostate and Wolffian duct development. Oncogene 21, 1899–1908 (2002). https://doi.org/10.1038/sj.onc.1205096

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205096

Keywords

Search

Quick links